| Shen, Wei Feng |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
| Active, not recruiting | 1/2 | 206 | RoW | LM-302 Injection | LaNova Medicines Zhejiang Co., Ltd. | Advanced Solid Tumor | 03/25 | 06/25 | | |
NCT04758897: Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161 | CNBG-Virogin Biotech (Shanghai) Ltd. | Advanced Malignant Solid Tumor | 03/22 | 12/22 | | |
Endo-mmfi, NCT06236594: Application of Multimodal Endoscopic Functional Imaging Technology in the Diagnosis of Common Gastrointestinal Diseases |
|
|
| Recruiting | N/A | 100 | RoW | | Beijing 302 Hospital | Gastrointestinal Disease | 12/24 | 12/24 | | |
NOD2-Pilot, NCT06782061: A Pilot Study on the Activation of NOD2 Receptors in Preterm Infants by Lactobacillus Reuteri DSM17938 |
|
|
| Not yet recruiting | N/A | 15 | NA | DSM17938+Routine clinical treatment | Nanfang Hospital, Southern Medical University | Preterm Infants | 06/25 | 12/25 | | |
| Du, Peng |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06750419: 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study |
|
|
| Recruiting | 3 | 82 | RoW | 89Zr-TLX250 PET/CT, 89Zr-DFO-girentuximab, 89Zr-girentuximab, 89Zr-DFO-TFP-GTX, 89Zirconium-labelled girentuximab | Telix Pharmaceuticals (Innovations) Pty Limited | Clear Cell Renal Cell Carcinoma | 06/26 | 06/26 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05337189: A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China |
|
|
| Recruiting | N/A | 482 | RoW | Urine DNA methylation analysis, URISAFE, medical imaging and/or cystoscopy and/or pathological examination | Creative Biosciences (Guangzhou) Co., Ltd., Guangzhou Xiangkang Medical Research Co., Ltd. | Bladder Cancer, Urocystitis, Urinary Bladder Stone, Urothelial Carcinoma | 12/24 | 12/24 | | |
